Bundang Seoul National University Hospital's First Pericardial Functional Assisted Impella...It's more effective than a pump and less burdensome than ECMO
Nov 18, 2025
Bundang Seoul National University Hospital announced that the cardiovascular intervention team led by Professor Chae In-ho of the Department of Circulatory Medicine performed the first case of the procedure 'Impella CP' on the 17th.
Impella is an ultra-small mechanical circulation device that sends blood to the aorta in place of the heart muscle inside the left ventricle. It reduces the heart burden during the treatment of cardiac shock or high-risk coronary artery surgery, and helps the heart to self-recover even if the blood pump function of the left ventricle drops significantly.
These impellas are inserted into the left ventricle in the form of a tube (catter) through a small incision in the thigh femoral artery, assisting heart function, and then removing it when it reaches a stable state.
The first procedure at Seoul National University Bundang Hospital was safely performed on high-risk coronary intervention patients under the guidance of Professor Chae In-ho and Cho Hyung-won of the Department of Circulatory Medicine, and the inserted impella was removed after stabilizing the patient's heart function for about a day.
Drug treatment and intra-aortic pumps, which have been used for cardiac shock, are limited in effect, and ECMO (Extra Membrane Oxygen Supply System) replaces the entire heart and lung functions, so complications such as bleeding and thrombosis are very burdensome. On the other hand, Impella is highly utilized in that it can effectively assist left ventricular function with minimal invasion.
Professor Chae In-ho said, "Impella is a treatment that can effectively respond to a rapid decline or suspension of ventricular function by inserting a pump motor into the heart with minimal invasion.". "We will continue to actively introduce innovative treatments to increase the survival rate of patients with severe heart disease in the future."
Meanwhile, Impella was approved by the Food and Drug Administration (FDA) in 2008 in the United States and is currently the most commonly used treatment for cardiac shock worldwide. In Korea, it was recently designated as a rare medical device with permission from the Ministry of Food and Drug Safety.
Impella is an ultra-small mechanical circulation device that sends blood to the aorta in place of the heart muscle inside the left ventricle. It reduces the heart burden during the treatment of cardiac shock or high-risk coronary artery surgery, and helps the heart to self-recover even if the blood pump function of the left ventricle drops significantly.
These impellas are inserted into the left ventricle in the form of a tube (catter) through a small incision in the thigh femoral artery, assisting heart function, and then removing it when it reaches a stable state.
The first procedure at Seoul National University Bundang Hospital was safely performed on high-risk coronary intervention patients under the guidance of Professor Chae In-ho and Cho Hyung-won of the Department of Circulatory Medicine, and the inserted impella was removed after stabilizing the patient's heart function for about a day.
Drug treatment and intra-aortic pumps, which have been used for cardiac shock, are limited in effect, and ECMO (Extra Membrane Oxygen Supply System) replaces the entire heart and lung functions, so complications such as bleeding and thrombosis are very burdensome. On the other hand, Impella is highly utilized in that it can effectively assist left ventricular function with minimal invasion.
Professor Chae In-ho said, "Impella is a treatment that can effectively respond to a rapid decline or suspension of ventricular function by inserting a pump motor into the heart with minimal invasion.". "We will continue to actively introduce innovative treatments to increase the survival rate of patients with severe heart disease in the future."
Meanwhile, Impella was approved by the Food and Drug Administration (FDA) in 2008 in the United States and is currently the most commonly used treatment for cardiac shock worldwide. In Korea, it was recently designated as a rare medical device with permission from the Ministry of Food and Drug Safety.
|
This article was translated by Naver AI translator.
